Evidence map›Paper›PMID 42733924›Full record

ArticleJTO clinical and research reports2026

Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report.

Minori Takamura, Kentaro Tamura, Risa Sugito, Naoko Takahashi, Shiko Honma, Masahiro Yoshida, Hiroshi Wakui, Hitomi Sekiguchi, Ryusuke Kizawa, Susumu Saito and 9 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Minori TakamuraDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kentaro TamuraDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Risa SugitoDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Naoko TakahashiDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Shiko HonmaDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Masahiro YoshidaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hiroshi WakuiDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hitomi SekiguchiDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Ryusuke KizawaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Susumu SaitoDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Sachi MatsubayashiDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Ayu KiritaniDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Keitaro OkudaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hirofumi UtsumiDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Saburo ItoDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Shunsuke MinagawaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takanori NumataDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hiromichi HaraDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Jun ArayaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is no established treatment for relapsed SCLC in patients with interstitial lung disease. We report the case of a 67-year-old man with idiopathic pulmonary fibrosis (IPF) receiving nintedanib who developed a postoperative relapse of SCLC. After cisplatin plus etoposide therapy, the patient developed an acute exacerbation of IPF, which improved with corticosteroid therapy. However, pleural dissemination and pulmonary metastases progressed, leading to the initiation of tarlatamab. During follow-up, transient ground-glass opacities appeared around pulmonary metastases. These opacities resolved, and tumor shrinkage was observed. The patient achieved a partial response without new toxicities, and the therapy was ongoing. Immunohistochemical analysis using an anti-delta-like ligand 3 antibody (SP347) reported strong expression in tumor cells but no detectable expression in adjacent normal or fibrotic lung tissue. This finding provides a possible biological rationale. This case suggests that tarlatamab may be a potential therapeutic option in selected patients with relapsed SCLC complicated by IPF.

Indexed as

Case reportDelta-like ligand 3Idiopathic pulmonary fibrosisInterstitial lung diseaseSmall cell lung cancerTarlatamab

Identifiers

PMID42733924
PMCPMC13571922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.